# Proof of Concept (POC) in Patients With Ischaemic Stroke

> **NCT01808261** · PHASE2 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 134 (actual)

## Conditions studied

- Cerebrovascular Accident

## Interventions

- **DRUG:** GSK249320 100/mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01808261
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-05-18
- **Primary completion:** 2014-07-28
- **Final completion:** 2014-07-28
- **Target enrollment:** 134 (ACTUAL)
- **Why stopped:** This study was terminated for futility.
- **Last updated:** 2017-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01808261

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01808261, "Proof of Concept (POC) in Patients With Ischaemic Stroke". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01808261. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*